Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Antibiotic prophylaxis before dental procedure vs placebo or no prophylaxis

Development of endocarditis due to other (non-dental) causes · Adults or children at increased risk of bacterial endocarditis (pre-existing cardiac condition) undergoing an invasive dental procedure

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures 2022 · Cochrane All outcomes
Only four cases developed endocarditis following non-dental medical interventions (within the past 180 days and with pre-existing cardiac indications for the use of prophylaxis), so assessment of the effects of…
0 studies
No studies found

Cephalomedullary nails vs extramedullary implants

Health‐related quality of life, early (≤ 4 months) · older adults (> 60 years of age) with extracapsular hip fractures

The review found no eligible studies for this question.

1 finding from 1 review

Cephalomedullary nails versus extramedullary implants for extracapsular hip fractures in older adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reverse total shoulder arthroplasty (RTSA) vs hemiarthroplasty

Self‐reported shoulder function · adults undergoing surgery for displaced proximal humeral fracturesa (2 trials)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating proximal humeral fractures in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Antibiotic resistance · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: aztreonam lysine for inhalation vs tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Survival · adults and children aged over 12 with CF and P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Support plus vs usual care

Stopping breastfeeding (any) at 9 months ‐ not reported · healthy breastfeeding women with healthy term babies

The review found no eligible studies for this question.

1 finding from 1 review

Support for healthy breastfeeding mothers with healthy term babies 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous ± oral steroids vs oral steroids alone

Complete or partial remission · minimal change disease in adults with nephrotic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mobility outcome · adults following hip fracture surgery

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving mobility after hip fracture surgery in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mobility outcome · adults following hip fracture surgery

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving mobility after hip fracture surgery in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found